No near-term upside for NxStage as Medicare maintains home hemodialysis status quo

Tue, 07/03/2012 - 4:00pm
Mass Device

The Centers for Medicare & Medicaid leave the home hemodialysis rule as it is, dashing some analysts' hopes of improved reimbursement status and a near-term upside for NxStage Medical.

CMS logo

The Centers for Medicare & Medicaid Services last night released an updated rule for reimbursement of home hemodialysis treatment that wasn't much of an update at all.

CMS maintained the reimbursement status quo, dashing some investors' hopes of a near-term upside for NxStage Medical (NSDQ:NXTM).

"This likely comes as no surprise to investors, and the status quo is likely already largely reflected in NXTM shares and consensus estimates," Leerink Swann analyst Danielle Antalffy wrote in a note to investors. "Still, we had hoped that CMS might at least make some minor improvements in home hemo reimbursement, potentially through higher training payments and/or more specific criteria as to which patients are deemed medically justifiable for extra treatments per week."


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.